| Thomas A Anzalone, MD | |
|
1202 S Tyler St, Covington, LA 70433-2330 | |
| (985) 898-4000 | |
| Not Available |
| Full Name | Thomas A Anzalone |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 32 Years |
| Location | 1202 S Tyler St, Covington, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285637710 | NPI | - | NPPES |
| 1681962 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 021569 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Tammany Parish Hospital | Covington, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Total Anesthesia Care Stph Llc | 0749255909 | 48 |
News Archive
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
The Dispensary of Hope, a Nashville-based not-for-profit social venture, is pleased to announce that seven new sites across the nation have been added to the Dispensary network, bringing the total number of sites to almost eighty. Apart from Tennessee, the locations of new sites include Pennsylvania, Michigan, Louisiana and Alabama, widening the scope of the Dispensary and providing opportunities to many different communities.
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.
Researchers at Northwestern University are using a novel dimensional method for distinguishing misbehavior that is expectable in early childhood versus that which is cause for clinical concern.
› Verified 8 days ago
| Entity Name | Total Anesthesia Care Stph Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669475190 PECOS PAC ID: 0749255909 Enrollment ID: O20040831000877 |
News Archive
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
The Dispensary of Hope, a Nashville-based not-for-profit social venture, is pleased to announce that seven new sites across the nation have been added to the Dispensary network, bringing the total number of sites to almost eighty. Apart from Tennessee, the locations of new sites include Pennsylvania, Michigan, Louisiana and Alabama, widening the scope of the Dispensary and providing opportunities to many different communities.
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.
Researchers at Northwestern University are using a novel dimensional method for distinguishing misbehavior that is expectable in early childhood versus that which is cause for clinical concern.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas A Anzalone, MD 120 Innwood Dr, Covington, LA 70433-9123 Ph: (985) 892-3225 | Thomas A Anzalone, MD 1202 S Tyler St, Covington, LA 70433-2330 Ph: (985) 898-4000 |
News Archive
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
The Dispensary of Hope, a Nashville-based not-for-profit social venture, is pleased to announce that seven new sites across the nation have been added to the Dispensary network, bringing the total number of sites to almost eighty. Apart from Tennessee, the locations of new sites include Pennsylvania, Michigan, Louisiana and Alabama, widening the scope of the Dispensary and providing opportunities to many different communities.
Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.
Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.
Researchers at Northwestern University are using a novel dimensional method for distinguishing misbehavior that is expectable in early childhood versus that which is cause for clinical concern.
› Verified 8 days ago
Gloria G Dunn, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1202 S Tyler St, Covington, LA 70433 Phone: 985-898-4000 | |
Mario S Claros-oliva, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1202 S Tyler St, Covington, LA 70433 Phone: 985-898-4000 | |
Maurice O Weilbaecher Jr., M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1202 S Tyler St, Covington, LA 70433 Phone: 985-898-4000 | |
Dr. Barry Aubrey Shelby, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 19164 Highway 40, Covington, LA 70435 Phone: 985-893-7190 | |
Dr. Brian Curtis Ball, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1978 North Hwy 190 Ste B, Covington, LA 70433 Phone: 985-373-6827 Fax: 985-900-2178 | |
Cathy Q Zhang, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1411 Ochsner Blvd Ste C, Covington, LA 70433 Phone: 985-807-1937 |